Topical Aprepitant in Clinical and Experimental Pruritus | Dermatology | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.186.91. Please contact the publisher to request reinstatement.
1.
Duval A, Dubertret L. Aprepitant as an antipruritic agent?  N Engl J Med. 2009;361(14):1415-141619797294PubMedGoogle ScholarCrossref
2.
Torres T, Fernandes I, Selores M, Alves R, Lima M. Aprepitant: evidence of its effectiveness in patients with refractory pruritus continues.  J Am Acad Dermatol. 2012;66(1):e14-e1522177649PubMedGoogle ScholarCrossref
3.
Ständer S, Siepmann D, Herrgott I, Sunderkötter C, Luger TA. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy.  PLoS One. 2010;5(6):e1096820532044PubMedGoogle ScholarCrossref
4.
Gerber PA, Buhren BA, Homey B. More on aprepitant for erlotinib-induced pruritus.  N Engl J Med. 2011;364(5):486-48721288112PubMedGoogle ScholarCrossref
5.
Wallengren J. Neuroanatomy and neurophysiology of itch.  Dermatol Ther. 2005;18(4):292-30316297000PubMedGoogle ScholarCrossref
6.
Hill R. NK1 (substance P) receptor antagonists—why are they not analgesic in humans?  Trends Pharmacol Sci. 2000;21(7):244-24610871891PubMedGoogle ScholarCrossref
7.
Mantyh PW. Neurobiology of substance P and the NK1 receptor.  J Clin Psychiatry. 2002;63:(suppl 11)  6-1012562137PubMedGoogle Scholar
Research Letter
Aug 2012

Topical Aprepitant in Clinical and Experimental Pruritus

Author Affiliations

Author Affiliations: Department of Dermatology, Skane University Hospital, Lund, Sweden.

Arch Dermatol. 2012;148(8):957-959. doi:10.1001/archdermatol.2012.1018

Peroral aprepitant is a nonpeptide inhibitor of tachykinin receptor NK1 approved for use as an antiemetic drug for chemotherapy-induced nausea. Duval and Dubertret1 first reported that peroral aprepitant effectively reduced pruritus in 3 patients with Sézary syndrome. Similar results were obtained later for 6 of 7 patients with erythrodermic cutaneous T-cell lymphoma.2 Ständer et al3 reported an open-label study of 20 patients with chronic pruritus treated for a week with peroral aprepitant. It has been suggested that the effects of aprepitant are related to its preventing of mast-cell activation in the skin.4 The aim of the present study was to test this hypothesis with topical aprepitant.

×